Buparlisib , an oral pan-PI3K inhibitor for the treatment of breast cancer (Q34461019)

2 August 2017

1 reference

title

Buparlisib , an oral pan-PI3K inhibitor for the treatment of breast cancer (English)

1 reference

2 August 2017

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25645727%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Giorgio Valabrega

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25645727%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Filippo Montemurro

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25645727%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

author name string

Andrea Milani

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25645727%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Rossella Martinello

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25645727%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Caterina Aversa

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25645727%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Maurizio Scaltriti

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25645727%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

language of work or name

English

0 references

publication date

3 February 2015

1 reference

Expert Opinion on Investigational Drugs

2 August 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25645727%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

volume

24

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25645727%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25645727%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

page(s)

421-431

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25645727%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

cites work

Cancer statistics, 2013

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1008132

Comprehensive molecular portraits of human breast tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1008132

Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1008132

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1008132

Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1008132

Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1008132

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1008132

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1008132

Tamoxifen as initial endocrine therapy for metastatic breast cancer: long term follow-up of two Piedmont Oncology Association (POA) trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1008132

Overcoming endocrine therapy resistance by signal transduction inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1008132

Biomarkers of drugs targeting HER-family signalling in cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1008132

Endocrine resistance associated with activated ErbB system in breast cancer cells is reversed by inhibiting MAPK or PI3K/Akt signaling pathways.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1008132

Biological determinants of endocrine resistance in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1008132

mTOR signaling in growth control and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1008132

Mutations in the phosphatidylinositol 3-kinase pathway: role in tumor progression and therapeutic implications in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1008132

PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1008132

PIK3CA mutations are associated with lower rates of pathologic complete response to anti-human epidermal growth factor receptor 2 (her2) therapy in primary HER2-overexpressing breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1008132

The phosphatidyl inositol 3-kinase signaling network: implications for human breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1008132

Targeting the phosphoinositide 3-kinase pathway in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1008132

Biomarker analyses in CLEOPATRA: a phase III, placebo-controlled study of pertuzumab in human epidermal growth factor receptor 2-positive, first-line metastatic breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1008132

Mutational analysis of PI3K/AKT signaling pathway in tamoxifen exemestane adjuvant multinational pathology study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1008132

PI3K pathway inhibitors: better not left alone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1008132

Akt-induced endocrine therapy resistance is reversed by inhibition of mTOR signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1008132

Cross-talk between estrogen receptor and growth factor pathways as a molecular target for overcoming endocrine resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1008132

Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor-positive human breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1008132

Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1008132

Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1008132

Identification and characterization of NVP-BKM120, an orally available pan-class I PI3-kinase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1008132

Identification of NVP-BKM120 as a Potent, Selective, Orally Bioavailable Class I PI3 Kinase Inhibitor for Treating Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1008132

Preclinical modeling of combined phosphatidylinositol-3-kinase inhibition with endocrine therapy for estrogen receptor-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1008132

ERα-dependent E2F transcription can mediate resistance to estrogen deprivation in human breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1008132

Combining a PI3K inhibitor with a PARP inhibitor provides an effective therapy for BRCA1-related breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1008132

PI3K inhibition impairs BRCA1/2 expression and sensitizes BRCA-proficient triple-negative breast cancer to PARP inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1008132

Angiogenesis selectively requires the p110alpha isoform of PI3K to control endothelial cell migration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1008132

Characterization of the mechanism of action of the pan class I PI3K inhibitor NVP-BKM120 across a broad range of concentrations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1008132

Multiorgan metastasis of human HER-2+ breast cancer in Rag2-/-;Il2rg-/- mice and treatment with PI3K inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1008132

Phosphatidylinositide dependent kinase deficiency increases anxiety and decreases GABA and serotonin abundance in the amygdala.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1008132

Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1008132

Phase I dose-escalation study of buparlisib (BKM120), an oral pan-class I PI3K inhibitor, in Japanese patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1008132

Stand up to cancer phase Ib study of pan-phosphoinositide-3-kinase inhibitor buparlisib with letrozole in estrogen receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1008132

Phase I dose-escalation and -expansion study of buparlisib (BKM120), an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1008132

PI3K pathway activation in breast cancer is associated with the basal-like phenotype and cancer-specific mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1008132

Targeting the phosphatidylinositol 3-kinase signaling pathway in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1008132

Trastuzumab-resistant cells rely on a HER2-PI3K-FoxO-survivin axis and are sensitive to PI3K inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1008132

NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1008132

Phosphoinositide 3-kinase and Akt are essential for Sonic Hedgehog signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1008132

Crosstalk between hedgehog and other signaling pathways as a basis for combination therapies in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1008132

Advance care planning: ensuring that the patient's voice is heard

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1008132

Critical role for the p110alpha phosphoinositide-3-OH kinase in growth and metabolic regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1008132

mTOR and cancer: insights into a complex relationship

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1008132

mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1008132

Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1008132

AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1008132

PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1008132

mTORC1 inhibition is required for sensitivity to PI3K p110α inhibitors in PIK3CA-mutant breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1008132

10.1517/13543784.2015.1008132

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25645727%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

1 reference